Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
uPAR siRNA
- Development stage
- Preclinical
- Lead developer
- University of Illinois, Urbana-Champaign
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
uPAR siRNA is a small interfering RNA (siRNA) therapeutic candidate designed to silence the expression of the urokinase-type plasminogen activator receptor (uPAR). uPAR is a cell surface glycoprotein often overexpressed in various malignancies, including glioblastoma multiforme (GBM), where it promotes tumor cell invasion, angiogenesis, and survival. By transcriptionally knocking down uPAR, this agent induces p53-mediated apoptosis and inhibits angiogenic signaling pathways, such as those involving angiogenin and angiopoietin-1. Research conducted at the University of Illinois College of Medicine has demonstrated that uPAR siRNA, often delivered via plasmid (puPAR-Si) or in combination with uPA siRNA (bicistronic construct U2), significantly reduces tumor growth and angiogenesis in intracranial glioblastoma xenograft models.
- Other names
- urokinase-type plasminogen activator receptor siRNAuPAR-targeted siRNA
02
Targets
PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on uPAR siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on uPAR siRNA.